Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 7, Issue 23
December 12 2023
Issue Cover

Table of Contents

INSIDE BLOOD ADVANCES

Another step toward frontline BTK inhibitor therapy in MCL
Clinical Trials & Observations
Walter Hanel,Narendranath Epperla
View Articletitled, Another step toward frontline BTK inhibitor therapy in MCL
The challenge of eliciting opinions of gene therapy for SCD
Emily M. Limerick,Courtney D. Fitzhugh
View Articletitled, The challenge of eliciting opinions of gene therapy for SCD
Time to include IGLV3-21R110 status in CLL prognostication?
Richard Rosenquist
View Articletitled, Time to include IGLV3-21<sup>R110</sup> status in CLL prognostication?

CLINICAL TRIALS AND OBSERVATIONS

COVID-19 in patients with classic and variant hairy cell leukemia
Clinical Trials & Observations
Robert J. Kreitman,Theresa Yu,Lacey James,Julie Feurtado,Holly Eager,Olena Sierra Ortiz,Mory Gould,Jack Mauter,Hong Zhou,Peter D. Burbelo,Jeffrey I. Cohen,Hao-Wei Wang,Constance M. Yuan,Evgeny Arons
View Articletitled, COVID-19 in patients with classic and variant hairy cell leukemia
Early response markers predict survival after etoposide-based therapy of hemophagocytic lymphohistiocytosis
Clinical Trials & Observations
Bethany Verkamp,Adi Zoref-Lorenz,Brenton Francisco,Pearce Kieser,Joana Mack,Tucker Blackledge,Dafna Brik Simon,Joanne Yacobovich,Michael B. Jordan
View Articletitled, Early response markers predict survival after etoposide-based therapy of hemophagocytic lymphohistiocytosis
Supplemental data
Neurocognitive impairment associated with chronic morbidity in long-term survivors of Hodgkin Lymphoma
Clinical Trials & Observations
Nicholas S. Phillips,Daniel A. Mulrooney,AnnaLynn M. Williams,Wei Liu,Raja B. Khan,Matthew J. Ehrhardt,Tim Folse,Matthew Krasin,Deo Kumar Srivastava,Kirsten K. Ness,Melissa M. Hudson,Noah D. Sabin,Kevin R. Krull
View Articletitled, Neurocognitive impairment associated with chronic morbidity in long-term survivors of Hodgkin Lymphoma
Supplemental data
The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study
Clinical Trials & Observations
Nobuko Hijiya,Alexey Maschan,Carmelo Rizzari,Hiroyuki Shimada,Carlo Dufour,Hiroaki Goto,Hyoung Jin Kang,Terri Guinipero,Zeynep Karakas,Francisco Bautista,Stéphane Ducassou,Keon Hee Yoo,Christian Michel Zwaan,Frédéric Millot,Briana C. Patterson,Jill Samis,Miguel Izquierdo,Ksenia Titorenko,Sai Li,Darintr Sosothikul
View Articletitled, The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study
Supplemental data
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era
Clinical Trials & Observations
Sanjal H. Desai,Michael A Spinner,Andrew M. Evens,Alice Sykorova,Veronika Bachanova,Gaurav Goyal,Brad Kahl,Kathleen Dorritie,Jacues Azzi,Vaishalee P. Kenkre,Cheryl Chang,Jozef Michalka,Stephen M. Ansell,Brendon Fusco,Nuttavut Sumransub,Haris Hatic,Raya Saba,Uroosa Ibrahim,Elyse I. Harris,Harsh Shah,Nina Wagner-Johnston,Sally Arai,Grzegorz S. Nowakowski,Heidi Mocikova,Deepa Jagadeesh,Kristie A. Blum,Catherine Diefenbach,Siddharth Iyengar,K. C. Rappazzo,Firas Baidoun,Yun Choi,Vit Prochazka,Ranjana H. Advani,Ivana Micallef
View Articletitled, Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era
Supplemental data

GENE THERAPY

Preferences for potential benefits and risks for gene therapy in the treatment of sickle cell disease
Juan Marcos Gonzalez Sepulveda,Jui-Chen Yang,Shelby D. Reed,Ting-Hsuan Lee,Xinyi Ng,Sarah Stothers,Telba Irony,Martin Ho,Jennifer A. Rothman,Sherif Badawy,Carolyn Rowley,Jane Little,Nirmish R. Shah,Kaiwen Li,Marilyn J. Telen
View Articletitled, Preferences for potential benefits and risks for gene therapy in the treatment of sickle cell disease
Supplemental data
The challenge of eliciting opinions of gene therapy for SCD
Emily M. Limerick,Courtney D. Fitzhugh
View Articletitled, The challenge of eliciting opinions of gene therapy for SCD

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Evaluating the prevalence of inborn errors of immunity in adults with chronic immune thrombocytopenia or Evans syndrome
Clinical Trials & Observations
Debbie Jiang,Kira Rosenlind,Sarah Baxter,Terry Gernsheimer,Suleyman Gulsuner,Eric J. Allenspach,Siobán B. Keel
View Articletitled, Evaluating the prevalence of inborn errors of immunity in adults with chronic immune thrombocytopenia or Evans syndrome
Supplemental data

LYMPHOID NEOPLASIA

Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma
Ivana Spasevska,Ankush Sharma,Chloé B. Steen,Sarah E. Josefsson,Yngvild N. Blaker,Arne Kolstad,Even H. Rustad,Saskia Meyer,Kathrine Isaksen,Stalin Chellappa,Kushi Kushekhar,Klaus Beiske,Mette S. Førsund,Signe Spetalen,Harald Holte,Bjørn Østenstad,Marianne Brodtkorb,Eva Kimby,Johanna Olweus,Kjetil Taskén,Aaron M. Newman,Susanne Lorenz,Erlend B. Smeland,Ash A. Alizadeh,Kanutte Huse,June H. Myklebust
View Articletitled, Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma
Supplemental data
TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era
Daniel J. Landsburg,Jennifer JD Morrissette,Sunita D. Nasta,Stefan K. Barta,Stephen J. Schuster,Jakub Svoboda,Elise A. Chong,Adam Bagg
View Articletitled, <em>TP53</em> mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era
Supplemental data
High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma
Vincent Camus,Pierre-Julien Viailly,Fanny Drieux,Elena-Liana Veresezan,Pierre Sesques,Corinne Haioun,Eric Durot,Martine Patey,Cédric Rossi,Laurent Martin,Vinciane Rainville,Elodie Bohers,Philippe Ruminy,Dominique Penther,Sophie Kaltenbach,Julie Bruneau,Jérome Paillassa,Olivier Tournilhac,Alexandre Willaume,Chloé Antier,Julien Lazarovici,Emilie Lévêque,Pierre Decazes,Stéphanie Becker,David Tonnelet,Alina Berriolo-Riedinger,Philippe Gaulard,Hervé Tilly,Thierry Jo Molina,Alexandra Traverse-Glehen,Fabrice Jardin
View Articletitled, High <em>PDL1/PDL2</em> gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma
Supplemental data
Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma
Clinical Trials & Observations
Reem Karmali,Jeremy S. Abramson,Deborah M. Stephens,Jeffrey Barnes,Jane N. Winter,Shuo Ma,Juehua Gao,Jason Kaplan,Adam M. Petrich,Ephraim Hochberg,Tak Takvorian,Xinlei Mi,Valerie Nelson,Leo I. Gordon,Barbara Pro
View Articletitled, Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma
Supplemental data
Another step toward frontline BTK inhibitor therapy in MCL
Clinical Trials & Observations
Walter Hanel,Narendranath Epperla
View Articletitled, Another step toward frontline BTK inhibitor therapy in MCL

MYELOID NEOPLASIA

Runx1-R188Q germ line mutation induces inflammation and predisposition to hematologic malignancies in mice
Mohd Hafiz Ahmad,Mahesh Hegde,Waihay J. Wong,Mona Mohammadhosseini,Lisa Garrett,Anneliese Carrascoso,Neethu Issac,Benjamin Ebert,Jeffrey C. Silva,German Pihan,Lihua J. Zhu,Scot A. Wolfe,Anupriya Agarwal,P. Paul Liu,Lucio H. Castilla
View Articletitled, Runx1-R188Q germ line mutation induces inflammation and predisposition to hematologic malignancies in mice
Supplemental data
Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms
Clinical Trials & Observations
Benjamin H. Durham,Oshrat Hershkovitz-Rokah,Omar Abdel-Wahab,Mariko Yabe,Young Rock Chung,Gilad Itchaki,Maayan Ben-Sasson,Vered A. Asher-Guz,David Groshar,Seyram A. Doe-Tetteh,Tina Alano,David B. Solit,Ofer Shpilberg,Eli L. Diamond,Roei D. Mazor
View Articletitled, Mutant <em>PIK3CA</em> is a targetable driver alteration in histiocytic neoplasms
Supplemental data
The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencing
Anna Maierhofer,Nikita Mehta,Ryan A. Chisholm,Stephan Hutter,Constance Baer,Niroshan Nadarajah,Christian Pohlkamp,Ella R. Thompson,Paul A. James,Wolfgang Kern,Claudia Haferlach,Manja Meggendorfer,Torsten Haferlach,Piers Blombery
View Articletitled, The clinical and genomic landscape of patients with <em>DDX41</em> variants identified during diagnostic sequencing
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

E-cadherin/β-catenin expression is conserved in human and rat erythropoiesis and marks stress erythropoiesis
Rosa A. Krimpenfort,Santhe A. van der Meulen,Han Verhagen,Michel Driessen,Galina Filonova,Mark Hoogenboezem,Emile van den Akker,Marieke von Lindern,Micha Nethe
View Articletitled, E-cadherin/β-catenin expression is conserved in human and rat erythropoiesis and marks stress erythropoiesis
Supplemental data
A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease
Clinical Trials & Observations
Jane S. Hankins,Donald Brambilla,Michael B. Potter,Abdullah Kutlar,Robert Gibson,Allison A. King,Ana A. Baumann,Cathy Melvin,Victor R. Gordeuk,Lewis L. Hsu,Chinonyelum Nwosu,Jerlym S. Porter,Nicole M. Alberts,Sherif M. Badawy,Jena Simon,Jeffrey A. Glassberg,Richard Lottenberg,Lisa DiMartino,Sara Jacobs,Maria E. Fernandez,Hayden B. Bosworth,Lisa M. Klesges,Nirmish Shah,the Sickle Cell Disease Implementation Consortium
View Articletitled, A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease
Supplemental data

THROMBOSIS AND HEMOSTASIS

Minimum factor VIII levels to prevent joint bleeding in mild hemophilia A
Clinical Trials & Observations
Pasquale Agosti,Simona Maria Siboni,Sara Scardo,Adriana Torri,Roberta Gualtierotti,Flora Peyvandi
View Articletitled, Minimum factor VIII levels to prevent joint bleeding in mild hemophilia A
Supplemental data

TRANSPLANTATION

Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant
Andrew Lin,Samantha Brown,Stephanie Chinapen,Yeon Joo Lee,Susan K. Seo,Doris M. Ponce,Zainab Shahid,Sergio Giralt,Genovefa A. Papanicolaou,Miguel-Angel Perales,Brian C. Shaffer
View Articletitled, Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant
Supplemental data

RESEARCH LETTERS

Loss of GSK3β in hematopoietic stem cells results in normal hematopoiesis in mice
Grace Lee,Jude Franklin,Kalpana Gupta,Ruifu Liu,Lan Zhou,Christopher Ryder,Lukasz Sobieraj,Luke Molitor,Olubukola Abiona,Howard Meyerson,Indrani Das,Zachary Jackson,David N. Wald
View Articletitled, Loss of GSK3β in hematopoietic stem cells results in normal hematopoiesis in mice
Cranial radiotherapy has minimal benefit in children with central nervous system involvement in T-ALL
Clinical Trials & Observations
David O’Connor,Melvin Joy,Amir Enshaei,Amy Kirkwood,Pamela R. Kearns,Sujith Samarasinghe,John Moppett,Anthony V. Moorman,Ajay Vora
View Articletitled, Cranial radiotherapy has minimal benefit in children with central nervous system involvement in T-ALL
Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myeloma
Clinical Trials & Observations
Andrew J. Portuguese,Min Fang,Sherilyn A. Tuazon,Margot Pont,Xiaoyu Qu,Carolyn Shasha,Melissa Comstock,Justina Lyons,Gabriel Cole,Evan W. Newell,Emily Glynn,Lorinda A. Soma,Damian J. Green
View Articletitled, Acquired <em>CD38</em> gene deletion as a mechanism of tumor antigen escape in multiple myeloma
Supplemental data
Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization
Samantha M. Teierle,Ying Huang,Adam S. Kittai,Seema A. Bhat,Michael Grever,Kerry A. Rogers,Weiqiang Zhao,Daniel Jones,John C. Byrd,Matthew R. Avenarius,Nyla A. Heerema,Jennifer A. Woyach,Cecelia R. Miller
View Articletitled, Characteristics and outcomes of patients with CLL and <em>CDKN2A/B</em> deletion by fluorescence in situ hybridization
Supplemental data
Histiocytic neoplasm subtypes differ in their MAP2K1 mutational type
Jean-François Emile,Zofia Hélias-Rodzewicz,Benjamin H. Durham,Sébastien Héritier,Malik da Silva,Komel Younas,Fleur Cohen-Aubart,Omar Abdel-Wahab,Eli L. Diamond,Jean Donadieu,Julien Haroche
View Articletitled, Histiocytic neoplasm subtypes differ in their <em>MAP2K1</em> mutational type
Supplemental data
Loss of early myeloid donor cell engraftment into the central nervous system with nonmyeloablative conditioning
Erin E. Nolan,Willa Durose,Leyla A. Taghizadeh,Carina J. King,Ashish O. Gupta,Paul J. Orchard,Maggie Lorentson,Kai Braaten,Justin W. Furcich,Troy C. Lund
View Articletitled, Loss of early myeloid donor cell engraftment into the central nervous system with nonmyeloablative conditioning
Supplemental data
IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia
Charlotte Syrykh,Berta Pons-Brun,Núria Russiñol,Heribert Playa-Albinyana,Tycho Baumann,Martí Duran-Ferrer,Marta Kulis,Anna Carbó-Meix,Pablo Mozas,Miguel Alcoceba,Marcos González,Almudena Navarro-Bailón,Enrique Colado,Ángel R. Payer,Marta Aymerich,María J. Terol,Junyan Lu,Binyamin A. Knisbacher,Cynthia K. Hahn,Sílvia Ruiz-Gaspà,Anna Enjuanes,Catherine J. Wu,Gad Getz,Thorsten Zenz,Armando López-Guillermo,José I. Martín-Subero,Dolors Colomer,Julio Delgado,Elías Campo,Ferran Nadeu
View Articletitled, IGLV3-21<sup>R110</sup> mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia
Supplemental data
Time to include IGLV3-21R110 status in CLL prognostication?
Richard Rosenquist
View Articletitled, Time to include IGLV3-21<sup>R110</sup> status in CLL prognostication?

COMMENTARY

JAK2V617F and ischemic stroke: CHIP or CMD-NBV?
Clinical Trials & Observations
Giovanni Barosi,Vittorio Rosti,Robert Peter Gale
View Articletitled, JAK2<sup>V617F</sup> and ischemic stroke: CHIP or CMD-NBV?

ERRATUM

Pirillo C, Birch F, Tissot FS, et al. Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness. Blood Adv. 2022;6(10):3126-3141.
View Articletitled, Pirillo C, Birch F, Tissot FS, et al. Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness. <em>Blood Adv.</em> 2022;6(10):3126-3141.
All Issues

Advertisement intended for health care professionals

Time to revisit reduced-dose radiotherapy for PCNSL?
Lin A, Brown S, Chinapen S, et al. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant. Blood Adv. 2023;7(23):7153-7160.
Jalink M, Jacobs CF, Khwaja J, et al. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv. 2024;8(11):2622-2634.
Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes
Retreatment of multiple myeloma with previously refractory drugs

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals